TMS Co., Ltd. announced that it has entered into an exclusive worldwide license agreement with Hokkaido University (Location: Sapporo, Hokkaido; President: Kiyohiro Houkin; Hokkaido University), a national university corporation, concerning a therapeutic candidate for the treatment of spinal cord injury (the Substance). As part of its efforts to expand the pipeline, the Company has been searching for external innovations mainly from academia. In July 2022, the Company entered into an option agreement with Hokkaido University with regard to the Substance, which was identified in the course of such search, and has been evaluating the Substance on various aspects such as efficacy, safety, and marketability.

As a result, the Company exercised the option and decided to develop the Substance, now named TMS-010, as a candidate for spinal cord injury therapeutics.